

DRUGS

INTELLECTUAL
PROPERTYLITERATURE
& NEWS

COMPANIES

TARGETS

CHEMISTRY

SEQUENCES

► **DEALS**

THOMSON Pharma®



Thomson Pharma® is a dynamic information solution for the pharmaceutical and biotechnology industries. It features the best scientific, patent, and financial content offered by Thomson businesses. This premium content has been enhanced with powerful search tools and integrated into a single solution that professionals working at all stages of drug development can personalize to suit their needs.

Complete, detailed information on current and past deals

Through *Thomson Pharma*, you can access multiple types of content, including extensive, up-to-date coverage of current and past deals. With this information, you can structure similar deals, find out who's collaborating with whom and where companies are attempting to fill gaps in their pipelines, and gain an insight into the prevailing limits on deal values.

Through *Thomson Pharma*, you can:

- View both confirmed deals and options
- Investigate the companies involved, the deal status, start date and drugs/therapy areas associated with the deal
- Explore the key events that have occurred during the deal
- Examine a financial summary, including total payments made to date, expected total payments and payment tracker (payments both ways are recorded)
- Compare deals across the world — all local currency values are converted to US dollars (the exchange rate at the time of deal is also given)
- Search by value of deal (including absolute value or a range of values)



Deal Report

1 of 94

[Back to results](#)

OVERVIEW

EVENT HISTORY

FINANCIALS

SUMMARY

OVERVIEW

Use the tabs to find the associated content in that particular area

SUMMARY

Title	Aventis to develop Zealand's AVE-0010 formulations
Primary company	Zealand Pharma A/S
Partnering company	Aventis SA
Deal Type	Drug - Development/Commercialization
Drug(s) / Technology	AVE-0010 ; AVE-0010 (sustained release) , sanofi-aventis
Status	Active
Total Projected value (US\$)	~ 110 Million
Total realized to date (US\$)	> 10 Million
Therapy areas	Non-insulin dependent diabetes
Actions	Glucagon-like peptide 1 agonist; Insulin metabolism modulator; Insulin release stimulator; Hypoglycemic agent
Technologies	Sustained release formulation; Subcutaneous formulation; Peptide
Territories covered	World
Start date	25 June 2003

Link to a list of companies and drugs associated with the deal

OVERVIEW

1

Deal overview, contains links to the Literature & News Reports referenced

In June 2003, [Aventis](#) (now [sanofi-aventis](#)) acquired global rights to AVE-0010 (ZP-10), which was being evaluated as [once-daily](#) and [extended release](#) formulations, from [Zealand Pharma](#) [[494758](#)], [[511326](#)], [[555709](#)].

Event History contains information of how the deal has progressed over time

EVENT HISTORY		
Original Deal - 25-JUN-03		
Summary	Payment type	Value (US\$)
In June 2003, Aventis acquired global rights to AVE-0010 (ZP-10), which was being evaluated as once-daily and extended release formulations, from Zealand Pharma . Under the terms of the agreement, Aventis would assume responsibility for further development, regulatory approval, manufacturing, marketing and sales of the compound and would pay its part Zealand would receive an upfront payment of \$10 million; further milestone payments up to \$100 million were also anticipated. Further, Zealand would receive royalties on future product sales [494758], [511326].	Upfront Payment	\$ 10 Million
M&A Activity - 20-AUG-04		
Summary	Payment type	Value (US\$)
In August 2004, Aventis merged into Sanofi-Synthelabo to form sanofi-aventis [555709].		
Development Milestone - 03-MAR-05		
Summary	Payment type	Value (US\$)
In March 2005, sanofi-aventis reported that a phase IIa trial had been completed, triggering an undisclosed milestone payment to Zealand [588294].	Milestone Payment	

Summary information of the deal



Financial details — payment dates, and types recorded


FINANCIAL DETAIL						
Projected Values						
Payment type	Amount	US Exchange rate (period)	US\$ Amount	Ref		
Upfront Payment	10 Million (USD)	1	10 Million	494758		
Milestone Payment	< 100 Million (USD)	1	100 Million	494758		
Royalty Payment	Undisclosed	1		494758		
Payments from Aventis SA to Zealand Pharma A/S						
Event	Date	Payment type	Amount (local currency)	US Exchange (Period)	US\$ Amount	Ref
Original Deal	25 June 03	Upfront Payment	10 Million (USD)	1	10 Million	494758
Development Milestone	03 March 05	Milestone Payment	Undisclosed	1		588294

All payments converted to \$US for easy comparison. Local currency details are also included

FINANCIAL SUMMARY	
Projected Values [494758]	
Payment Type	US\$
Upfront Payment	10 Million
Milestone Payment	< 100 Million
Royalty Payment	undisclosed
Total value	~ 110 Million
Payment Tracker - from Aventis SA to Zealand Pharma A/S	
Payment Type	US\$
Upfront Payment	10 Million
Milestone Payment	undisclosed
Total Paid	> 10 Million

Financial summary

View the therapy areas with the most deals and the top deals makers



It is possible to click on the bars of the histogram, allowing you to see all the deals for a particular therapeutic area or company

Deals reports

Thomson Pharma gives you access to comprehensive deals reports that contain premium information pulled from a wide range of sources. The reports accumulate dynamically over time as more information becomes available, so you can follow the progress of a deal from first announcement to completion.

You can generate a deals report by using one of the many search options available on *Thomson Pharma*. You can link to a deals report via the content delivered directly to your personalized home page, the portlets on the Licensing and Business home page, or via a report focusing on a different area of content, such as a drug report or a company report. You can also find links to relevant deals when you browse actions, therapy areas or technology terms. The tabbed report makes it easy to find associated information.

Deals portlets

You can personalize your *Thomson Pharma* home page so that it is constantly updated with new deals content. This means you can be alerted whenever new or updated information becomes available within *Thomson Pharma*, helping you stay informed about the latest developments in your field.

Through the portlets on your personalized home page, you can:

- Receive alerts about new deals and developments in existing deals
- View all the new and updated deals added to *Thomson Pharma* in the last week
- Explore the top therapy areas or deal makers or partners for the chosen time period

Find out more at:
thomsonpharma.com



For further information,
please contact your regional
Thomson Scientific office.

Thomson Scientific Regional Head Offices:

Americas

Phone +1 800 336 4474
+1 215 386 0100

Europe, Middle East and Africa

Phone +44 20 7433 4000

Japan

Phone +81 3 5218 6500

Asia Pacific

Phone +65 6879 4118

Thomson Scientific Offices around the World:

Sydney, Australia
Rio de Janeiro, Brazil
Paris, France
Munich, Germany
Hong Kong
Bangalore, India
Tokyo, Japan
Mexico City, Mexico
Beijing, People's Republic of China
Seoul, Republic of Korea
Singapore
Taipei, Taiwan
London, United Kingdom
USA
Alexandria, Virginia
Ann Arbor, Michigan
Carlsbad, California
San Jose, California
East Haven, Connecticut
Lisle, Illinois
Portland, Maine
Horsham, Pennsylvania
Philadelphia, Pennsylvania

For complete contact information, visit:
scientific.thomson.com/contact